

PCI Launches High Containment Packaging Facility at Ireland Site, EU

Most recent EU acquisition and PCI's latest site to offer state-of-the-art contained packaging facility to global customers for potent compounds

Philadelphia, PA – April 25, 2018 – Today, leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) premiered its new contained packaging facility for the primary and secondary packaging of highly potent products at its newly acquired site near Dublin, Ireland, EU. This latest investment further demonstrates PCI's ability to provide its current and future customers with the highest standards of excellence in outsourced pharmaceutical packaging services.

PCI is the recognized global leader in the manufacturing of highly potent molecules at its purpose-built, award-winning contained manufacturing facility located at its Tredegar site in Wales, UK. This latest investment in contained packaging capabilities at the PCI Ireland site ensures PCI's ongoing commitment to delivering the highest standards of safety and regulatory adherence for specialized medicines. It is also the most recent part of PCI's strategic initiative to develop its High Containment Operations (HCO) services globally.

"We are very excited to officially launch our state-of-the-art high contained packaging facility here in Ireland," commented Bill Mitchell, President and CEO. "The recent acquisition of Millmount Healthcare and further investment in this newest specialized facility adds considerable capacity and capability to our global supply network, enabling us to meet our customers' ever changing and evolving needs in many different geographies. Moreover, as our fourth acquisition outside the US in the past four years, this expansion further demonstrates our ability to provide our clients with a comprehensive solution to any uncertainty brought upon by ongoing negotiations between the UK and EU as a result of the evolving Brexit situation."

"The Republic of Ireland has a thriving pharmaceutical and biotech community which PCI has been fortunate to support for many years. We have already received a tremendous response to the acquisition, and investments such as this high containment packaging facility are part of our strategic plan to continue business growth and service development for our customers. PCI is



proud to provide services for medicines destined to over 100 countries around the world, and the Dublin site itself to more than 50 countries.”

Since the acquisition of Millmount Healthcare, PCI has added approximately 30 positions at the Dublin area facilities and anticipates adding more than 100 positions over the next five years as the sites continue to expand and grow its operations.

PCI was supported in the planning and execution of its newest facility by [IDA Ireland](#).

About PCI Pharma Services

The global healthcare industry trusts PCI for the drug development solutions that increase their products' speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients' lives. For more information, please visit www.pciservices.com or follow us on Twitter at [@PCI_Social](#).

Contact

Chantel Richman / Carrie Lowe at becg

E: chantel.richman@becg.co.uk / carrie.lowe@becg.co.uk

T: +44 (0)7805 778 002 / +44 (0) 7554 014 188